Clinical trials
Phase 1 Liver Cirrhosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
63 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 2 |
| 2008 | 2 |
| 2009 | 6 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 11 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 8 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 37 |
| Unknown status | 14 |
| Recruiting | 5 |
| Not yet recruiting | 3 |
| Terminated | 3 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 5 |
| Baermed | 3 |
| Beijing Continent Pharmaceutical Co, Ltd. | 3 |
| Norgine | 3 |
| Bristol-Myers Squibb | 2 |
| GlaxoSmithKline | 2 |
| National Center for Research Resources (NCRR) | 2 |
| Vinmec Research Institute of Stem Cell and Gene Technology | 2 |
| Alentis Therapeutics AG | 1 |
| Anhui Provincial Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Liver Cirrhosis | 63 |
| Fibrosis | 8 |
| Non-alcoholic Fatty Liver Disease | 5 |
| Ascites | 3 |
| Liver Diseases | 3 |
| Biliary Atresia | 2 |
| Hepatic Insufficiency | 2 |
| Hepatitis C | 2 |
| Alcoholism | 1 |
| Carcinoma, Hepatocellular | 1 |
Trials
Showing 26 to 50 of 63. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.